|For Immediate Release:||Contact: Michael Drewniak
|Date: Wednesday August 22, 2012||609-777-2600|
In the past few years, researchers have identified multiple different neurobiological pathways, which represent potential targets for the development of drugs to positively impact learning and memory in individuals with Down syndrome.
RDS is a 501c3 non-profit foundation which funds research at leading institutions directed towards identifying safe and effective biomedical therapies to treat the intellectual challenges associated with Down syndrome. These studies now provide the promise of biomedical therapies for improving memory, learning and communication in individuals with Down syndrome, offering the potential for increased life opportunities.
For more information, go to www.researchds.org , or contact RDS: email@example.com or 877.863.2121.
|Contact Us|||||Privacy Notice|||||Legal Statement & Disclaimers|||||Accessibility Statement|